From the Journals

Peripheral neuropathy tied to mortality in adults without diabetes


 

Related conditions

The study confirms findings from prior studies that examined the prevalence of loss of peripheral sensation in populations of older adults with and without diabetes, said Elsa S. Strotmeyer, PhD, MPH, associate professor of epidemiology at the University of Pittsburgh. “The clinical significance of the loss of peripheral sensation in older adults without diabetes is not fully appreciated,” she said.

A limitation of the study is that peripheral neuropathy was not a clinical diagnosis. “Monofilament testing at the foot is a quick clinical screen for decreased lower-extremity sensation that likely is a result of sensory peripheral nerve decline,” Dr. Strotmeyer said.

Another limitation is that death certificates are less accurate than medical records for determining cause of death.

“Past studies have indicated that peripheral nerve decline is related to common conditions in aging such as the metabolic syndrome and cardiovascular disease, cancer treatment, and physical function loss,” Dr. Strotmeyer said. “Therefore it is not surprising that is related to mortality as these conditions in aging are associated with increased mortality. Loss of peripheral sensation at the foot may also be related to fall injuries, and mortality from fall injuries has increased dramatically in older adults over the past several decades.”

Prior research has suggested that monofilament testing may play a role in screening for fall risk in older adults without diabetes, Dr. Strotmeyer added.

“For older adults both with and without diabetes, past studies have recommended monofilament testing be incorporated in geriatric screening for fall risk. Therefore, this article expands implications of clinical importance to understanding the pathology and consequences of loss of sensation at the foot in older patients,” she said.

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute. Dr. Hicks, Dr. Selvin, and a coauthor, Kunihiro Matsushita, MD, PhD, disclosed NIH grants. In addition, Dr. Selvin disclosed personal fees from Novo Nordisk and grants from the Foundation for the National Institutes of Health outside the submitted work, and Dr. Matsushita disclosed grants and personal fees from Fukuda Denshi outside the submitted work. Dr. Strotmeyer receives funding from the National Institute on Aging and the National Institute of Arthritis and Musculoskeletal and Skin Diseases and is chair of the health sciences section of the Gerontological Society of America.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Reworked OxyContin fails to cut overall opioid abuse, FDA panel says
Journal of Clinical Outcomes Management
Health Care Disparities Among Adolescents and Adults With Sickle Cell Disease: A Community-Based Needs Assessment to Inform Intervention Strategies
Journal of Clinical Outcomes Management
FDA orders stronger warnings on benzodiazepines
Journal of Clinical Outcomes Management
‘Overwhelming evidence’ FDA’s opioid approval process is shoddy
Journal of Clinical Outcomes Management
Children’s opioid harms vary by race, location
Journal of Clinical Outcomes Management
FDA issues new NSAIDs warning for second half of pregnancy
Journal of Clinical Outcomes Management
Diabetic neuropathic pain linked to brain bioenergic anomalies
Journal of Clinical Outcomes Management
Sleep apnea found to impact pain severity in younger adults
Journal of Clinical Outcomes Management
Cognitive Behavioral Therapy Plus Placebo Is Inferior to NSAID Therapy for Arthritis Pain
Journal of Clinical Outcomes Management
Joint guidelines favor antibody testing for certain Lyme disease manifestations
Journal of Clinical Outcomes Management